Evaluation of the short term efficacy and tolerability of a combined nutraceutical with lipid-lowering properties: a randomized clinical trial

  • Arrigo F. G. Cicero
  • Marilisa Bove
  • Beatrice Gerocarni
  • Marina Giovannini
  • Claudio Borghi
Original Article


This is a double-blind, placebo-controlled clinical trial on a combined nutraceutical non containing statin-like substances in 40 patients affected by primary polygenic hypercholesterolemia. After 4 weeks of ATP III life-style improvement, patients were randomized to assume a combined nutraceutical or placebo 1 pill/day for 8 weeks. The tested nutraceutical contained octacosanols, tocotrienols and polymethoxylated flavones (offered by Ca.Di.Group Srl, Rome, Italy). When comparing the combined nutraceutical effect with the one of placebo, we observed that the combined nutraceutical assumption was associated with a significantly higher decrease in total cholesterol (p < 0.001), LDL-cholesterol (p < 0.001), triglycerides (p < 0.001) and non HDL-cholesterol (p < 0.001) than the control group. In the short term, the tested combined nutraceutical is well-tolerated and efficacious in reducing plasma lipid levels in subjects affected by primary polygenic hypercholesterolemia.


Hypercholesterolemia Nutraceuticals Octacosanols Tocotrienols Polymethoxylated flavones 


Conflict of interest



  1. 1.
    Baigent C, Keech A, Kearney PM et al (2005) Cholesterol treatment trialists’ (CTT) collaboratorsefficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278CrossRefGoogle Scholar
  2. 2.
    Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N (2010) Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 170(12):1024–1031CrossRefGoogle Scholar
  3. 3.
    Jacobson TA (2008) Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 83(6):687–700CrossRefGoogle Scholar
  4. 4.
    Cicero AFG, Ertek S (2008) Natural sources of antidyslipidaemic agents: is there an evidence-based approach for their prescription? Med J Nutr Metab 1(2):85–93CrossRefGoogle Scholar
  5. 5.
    Shukla SK, Gupta S, Ojha SK, Sharma SB (2010) Cardiovascular friendly natural products: a promising approach in the management of CVD. Nat Prod Res 24(9):873–898CrossRefGoogle Scholar
  6. 6.
    Lu Z, Kou W, Du B et al (2008) Chinese Coronary Secondary Prevention Study Group Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 101(12):1689–1693CrossRefGoogle Scholar
  7. 7.
    Klimek M, Wang S, Ogunkanmi A (2009) Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. P T 34(6):313–327Google Scholar
  8. 8.
    Marinangeli CP, Jones PJ, Kassis AN, Eskin MN (2010) Policosanols as nutraceuticals: fact or fiction. Crit Rev Food Sci Nutr 50(3):259–267CrossRefGoogle Scholar
  9. 9.
    Qureshi AA, Sami SA, Salser WA, Khan FA (2002) Dose-dependent suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans. Atherosclerosis 161(1):199–207CrossRefGoogle Scholar
  10. 10.
    Baliarsingh S, Beg ZH, Ahmad J (2005) The therapeutic impacts of tocotrienols in type 2 diabetic patients with hyperlipidemia. Atherosclerosis 182(2):367–374CrossRefGoogle Scholar
  11. 11.
    Geohas J, Daly A, Juturu V, Finch M, Komorowski JR (2007) Chromium picolinate and biotin combination reduces atherogenic index of plasma in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Am J Med Sci 333(3):145–153CrossRefGoogle Scholar
  12. 12.
    NCEP ATP III Expert Panel (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRefGoogle Scholar
  13. 13.
    Kraft K (2009) Complementary/Alternative medicine in the context of prevention of disease and maintenance of health. Prev Med 49(2–3):88–92CrossRefGoogle Scholar
  14. 14.
    Johnston C (2009) Functional foods as modifiers of cardiovascular disease. Am J Lifestyle Med 3(1 Suppl):39S–43SCrossRefGoogle Scholar
  15. 15.
  16. 16.
    Massaro M, Scoditti E, Carluccio MA, De Caterina R (2010) Nutraceuticals and prevention of atherosclerosis: focus on omega-3 polyunsaturated fatty acids and Mediterranean diet polyphenols. Cardiovasc Ther 28(4):e13–e19CrossRefGoogle Scholar
  17. 17.
    Ramprasath VR, Jones PJ (2010) Anti-atherogenic effects of resveratrol. Eur J Clin Nutr 64(7):660–668CrossRefGoogle Scholar
  18. 18.
    Marangoni F, Poli A (2010) Phytosterols and cardiovascular health. Pharmacol Res 61(3):193–199CrossRefGoogle Scholar
  19. 19.
    Preiss D, Sattar N (2009) Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol 70(6):815–828CrossRefGoogle Scholar
  20. 20.
    Cicero AFG, Brancaleoni M, Laghi L, Donati F, Mino M (2005) Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complem Ther Med 13:273–278CrossRefGoogle Scholar
  21. 21.
    Roza JM, Xian-Liu Z, Guthrie N (2007) Effect of citrus flavonoids and tocotrienols on serum cholesterol levels in hypercholesterolemic subjects. Altern Ther Health Med 13(6):44–48Google Scholar
  22. 22.
    Prasad GV, Wong T, Meliton G, Bhaloo S (2002) Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 74(8):1200–1201CrossRefGoogle Scholar
  23. 23.
    Oliaro-Bosso S, Calcio Gaudino E, Mantegna S, Giraudo E, Meda C, Viola F, Cravotto G (2009) Regulation of HMGCoA reductase activity by policosanol and octacosadienol, a new synthetic analogue of octacosanol. Lipids 44(10):907–916CrossRefGoogle Scholar
  24. 24.
    Kurowska EM, Manthey JA, Casaschi A, Theriault AG (2004) Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxyflavone, tangeretin. Lipids 39(2):143–151Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Arrigo F. G. Cicero
    • 1
  • Marilisa Bove
    • 1
  • Beatrice Gerocarni
    • 1
  • Marina Giovannini
    • 1
  • Claudio Borghi
    • 1
  1. 1.Internal Medicine, Aging and Kidney Diseases DepartmentUniversity of BolognaBolognaItaly

Personalised recommendations